About BioTime (NYSEAMERICAN:BTX)
BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology. Its clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its facial aesthetics product, Renevia, is a potential treatment for facial lipoatrophy. It is in a pivotal clinical trial in Europe to assess its safety and efficacy in restoring normal skin contours in patients whose subcutaneous fat, or adipose tissue, has been lost due to the use of certain drugs often used to treat patients with human immune virus. OpRegen is its lead product for ophthalmological disorders. It is a suspension of retinal pigment epithelial cells that are derived from pluripotent stem cells.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
SymbolNYSEAMERICAN:BTXPrevious Symbol: NYSEMKT:BTX
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-25.71%
Return on Assets-24.61%
Frequently Asked Questions for BioTime (NYSEAMERICAN:BTX)
What is BioTime's stock symbol?
BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."
How were BioTime's earnings last quarter?
BioTime, Inc. (NYSEAMERICAN:BTX) announced its quarterly earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.06. The biotechnology company had revenue of $1.27 million for the quarter, compared to analysts' expectations of $1.75 million. BioTime had a negative return on equity of 25.71% and a negative net margin of 3,209.19%. View BioTime's Earnings History.
Where is BioTime's stock going? Where will BioTime's stock price be in 2017?
2 equities research analysts have issued 12 month price objectives for BioTime's stock. Their forecasts range from $6.00 to $6.50. On average, they expect BioTime's share price to reach $6.25 in the next twelve months. View Analyst Ratings for BioTime.
Are investors shorting BioTime?
BioTime saw a decline in short interest in the month of October. As of October 31st, there was short interest totalling 6,767,992 shares, a decline of 0.9% from the October 13th total of 6,827,321 shares. Based on an average daily trading volume, of 417,019 shares, the short-interest ratio is currently 16.2 days. Currently, 5.7% of the company's stock are short sold.
Who are some of BioTime's key competitors?
Some companies that are related to BioTime include Aduro Biotech (ADRO), Alder BioPharmaceuticals (ALDR), Deciphera Pharmaceuticals (DCPH), PTC Therapeutics (PTCT), Reata Pharmaceuticals (RETA), ZIOPHARM Oncology (ZIOP), Rigel Pharmaceuticals (RIGL), Axovant Sciences (AXON), G1 THERAPEUTICS (GTHX), Vanda Pharmaceuticals (VNDA), Madrigal Pharmaceuticals (MDGL), Keryx Biopharmaceuticals (KERX), Paratek Pharmaceuticals (PRTK), Adaptimmune Therapeutics PLC (ADAP), Coherus BioSciences (CHRS), Karyopharm Therapeutics (KPTI), Urogen Pharma (URGN) and Nightstar Therapeutics PLC Sponsored ADR (NITE).
Who are BioTime's key executives?
BioTime's management team includes the folowing people:
- Alfred D. Kingsley, Chairman of the Board (Age 74)
- Aditya P. Mohanty, Co-Chief Executive Officer, Director (Age 50)
- Michael D. West Ph.D., Co-Chief Executive Officer, Director (Age 63)
- Russell L. Skibsted, Chief Financial Officer (Age 58)
- Judith Segall, Vice President, Secretary (Age 61)
- Stephana Eilene Patton Ph.D., J.D., General Counsel (Age 46)
- Deborah J. Andrews, Independent Director (Age 59)
- Neal C. Bradsher, Independent Director (Age 51)
- Stephen C. Farrell CPA, Independent Director (Age 52)
- Michael H. Mulroy, Independent Director (Age 51)
Who owns BioTime stock?
BioTime's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Broadwood Capital Inc. (22.64%), IndexIQ Advisors LLC (0.22%), Family Management Corp (0.15%), GSA Capital Partners LLP (0.14%), Dimensional Fund Advisors LP (0.13%) and Schwab Charles Investment Management Inc. (0.09%). Company insiders that own BioTime stock include Aditya P Mohanty, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime.
Who sold BioTime stock? Who is selling BioTime stock?
BioTime's stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc. and Russell Investments Group Ltd.. View Insider Buying and Selling for BioTime.
Who bought BioTime stock? Who is buying BioTime stock?
BioTime's stock was purchased by a variety of institutional investors in the last quarter, including Broadwood Capital Inc., IndexIQ Advisors LLC, GSA Capital Partners LLP, Family Management Corp, Dimensional Fund Advisors LP and Jane Street Group LLC. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime.
How do I buy BioTime stock?
Shares of BioTime can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioTime's stock price today?
One share of BioTime stock can currently be purchased for approximately $2.65.
How big of a company is BioTime?
BioTime has a market capitalization of $350.75 million.
How can I contact BioTime?
BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.
MarketBeat Community Rating for BioTime (BTX)MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for BioTime (NYSEAMERICAN:BTX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Buy|
|Consensus Rating Score: ||1.83||1.50||2.25||2.80|
|Ratings Breakdown: ||2 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|3 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|2 Sell Rating(s)|
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$5.08||$5.33||$5.33||$6.75|
|Price Target Upside: ||113.59% upside||102.02% upside||94.65% upside||103.93% upside|
Consensus Price Target History for BioTime (NYSEAMERICAN:BTX)
Analysts' Ratings History for BioTime (NYSEAMERICAN:BTX)
(Data available from 11/25/2015 forward)
|6/19/2017||Ladenburg Thalmann Financial Services||Reiterated Rating||Buy||$6.00 -> $6.50|
|3/31/2017||Raymond James Financial, Inc.||Initiated Coverage||Outperform -> Outperform||$6.00|
|4/7/2016||Chardan Capital||Initiated Coverage||Buy|
|4/2/2016||Oppenheimer Holdings, Inc.||Reiterated Rating||Buy|
Earnings History and Estimates Chart for BioTime (NYSEAMERICAN:BTX)
Earnings History by Quarter for BioTime (NYSEAMERICAN BTX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/3/2016||Q316||($0.14)||($0.08)||$1.46 million||$1.50 million||View||N/A|
|8/9/2016||Q216||($0.17)||($0.11)||$1.75 million||$1.27 million||View||N/A|
|5/10/2016||Q116||($0.14)||($0.19)||$1.43 million||$2.10 million||View||N/A|
|5/11/2015||Q115||($0.13)||$1.10 million||$1.30 million||View||N/A|
|8/12/2014||Q214||($0.16)||$362.25 million||$300.08 million||View||N/A|
|5/12/2014||Q114||($0.14)||$0.61 million||$1.07 million||View||N/A|
|3/18/2013||Q412||($0.12)||$1.70 million||$1.20 million||View||N/A|
Earnings Estimates for BioTime (NYSEAMERICAN:BTX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for BioTime (NYSEAMERICAN:BTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for BioTime (NYSEAMERICAN BTX)
Insider Trades by Quarter for BioTime (NYSEAMERICAN BTX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/13/2017||Broadwood Partners, L.P.||Director||Buy||2,692,307||$2.60||$6,999,998.20|| |
|8/23/2017||Russell Skibsted||CFO||Buy||2,000||$2.64||$5,280.00|| |
|8/22/2017||Broadwood Partners, L.P.||Director||Buy||10,000||$2.60||$26,000.00|| |
|8/22/2017||Michael D. West||CEO||Buy||2,000||$2.60||$5,200.00|| |
|8/21/2017||Aditya P. Mohanty||CEO||Buy||7,500||$2.50||$18,750.00|| |
|8/21/2017||Deborah J Andrews||Director||Buy||2,396||$2.50||$5,990.00|| |
|7/31/2017||Broadwood Partners, L.P.||Director||Buy||150,000||$2.80||$420,000.00|| |
|6/16/2017||Deborah J Andrews||Director||Buy||2,000||$2.95||$5,900.00|| |
|5/16/2017||Deborah J Andrews||Director||Buy||2,000||$3.21||$6,420.00|| |
|2/15/2017||Broadwood Partners, L.P.||Director||Buy||2,222,222||$2.70||$5,999,999.40|| |
|6/21/2016||Broadwood Partners Lp||Director||Buy||2,732,636||$2.39||$6,531,000.04|| |
|1/20/2016||Broadwood Partners Lp||Director||Buy||300,000||$2.35||$705,000.00|| |
|11/6/2015||Alfred D Kingsley||Insider||Sell||100,000||$3.83||$383,000.00|| |
|11/6/2015||Stephen C Farrell||Director||Buy||50,000||$3.83||$191,500.00|| |
|8/26/2015||Deborah J Andrews||Director||Buy||2,000||$2.82||$5,640.00|| |
|8/18/2015||Stephen Lahue Cartt||Director||Buy||75,000||$2.80||$210,000.00|| |
|10/8/2014||David Schlachet||Director||Buy||32,050||$3.12||$99,996.00|| |
|7/22/2014||Broadwood Partners Lp||Director||Buy||370,000||$2.65||$980,500.00|| |
|7/22/2014||Michael D West||CEO||Sell||270,000||$2.65||$715,500.00|| |
|7/22/2014||Robert Peabody||CFO||Sell||100,000||$2.65||$265,000.00|| |
|6/17/2014||William P Phd Tew||Insider||Sell||30,000||$3.07||$92,100.00|| |
|6/16/2014||Broadwood Partners Lp||Director||Buy||1,000,000||$2.50||$2,500,000.00|| |
|5/16/2014||Broadwood Partners Lp||Director||Buy||300,000||$2.45||$735,000.00|| |
|5/8/2014||Broadwood Partners Lp||Director||Buy||300,000||$2.44||$732,000.00|| |
|5/1/2014||Broadwood Partners Lp||Director||Buy||2,000,000||$2.52||$5,040,000.00|| |
|2/25/2014||Broadwood Partners Lp||Director||Buy||500,000||$3.74||$1,870,000.00|| |
|12/30/2013||Neal C Bradsher||Director||Buy||300,042||$3.51||$1,053,147.42|| |
|11/20/2013||William P Phd Tew||Insider||Sell||13,860||$3.76||$52,113.60|| |
|9/12/2013||Stephen C Farrell||Director||Buy||11,213||$3.89||$43,618.57|| |
|8/20/2013||Stephen C Farrell||Director||Buy||4,187||$3.65||$15,282.55|| |
|8/12/2013||Eschenbach Andrew C Von||Director||Buy||3,000||$3.69||$11,070.00|| |
|3/28/2013||Broadwood Partners Lp||Director||Buy||200,000||$3.81||$762,000.00|| |
|11/15/2012||Broadwood Partners Lp||Director||Buy||344,828||$2.90||$1,000,001.20|| |
Latest Headlines for BioTime (NYSEAMERICAN BTX)
BioTime (NYSEAMERICAN BTX) Chart for Saturday, November, 25, 2017